Literature DB >> 27456361

High expression of BAG3 predicts a poor prognosis in human medulloblastoma.

Dong Yang1,2, Ji Zhou2,3, Hao Wang1,3, Yutao Wang1,2, Ge Yang1,2, Yundong Zhang4,5.   

Abstract

Bcl2-associated athanogene 3 (BAG3), a co-chaperone of the heat shock protein (Hsp) 70, regulates various physiological and pathological processes. However, its role in human medulloblastoma has not been clarified. First of all, the expression of BAG3 was examined in formalin-fixed, paraffin-embedded specimens by immunohistochemical staining. And then, the prognostic role of BAG3 was analyzed in 51 medulloblastoma samples. Finally, the roles of BAG3 in the proliferation, migration, and invasion of Daoy medulloblastoma cell were investigated using a specific short hairpin RNA (shRNA). The expression of BAG3 in medulloblastoma tissues was higher than nontumorous samples. Furthermore, BAG3 overexpression significantly correlated with poor prognosis of patients with medulloblastoma. The overall survival and tumor-free survival in patients with BAG3 low expression were higher than high expression. Univariate and multivariate analysis showed that BAG3 overexpression was an independent prognostic marker for medulloblastoma. After the BAG3 knockdown, the Daoy cells exhibited decreased the ability to proliferate and form neurosphere. The preliminary mechanism study showed that overexpression of BAG3 might facilitate the cell cycle transition from G1 to S phase by modulating the cyclin-dependent kinase 2 (CDK2) and cyclin E expression. Additionally, we found that BAG3 might enhance the medulloblastoma cell migratory and invasive ability. In summary, BAG3 overexpression may regulate the survival and invasive properties of medulloblastoma and may serve as a potential therapy target for medulloblastoma.

Entities:  

Keywords:  BAG3; Immunohistochemistry; Medulloblastoma; Tumor

Mesh:

Substances:

Year:  2016        PMID: 27456361     DOI: 10.1007/s13277-016-5197-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  33 in total

1.  Regulation by heavy metals and temperature of the human BAG-3 gene, a modulator of Hsp70 activity.

Authors:  Maria Gabriella Pagliuca; Rosa Lerose; Stefania Cigliano; Arturo Leone
Journal:  FEBS Lett       Date:  2003-04-24       Impact factor: 4.124

Review 2.  Tumour invasion and matrix metalloproteinases.

Authors:  Myriam Polette; Béatrice Nawrocki-Raby; Christine Gilles; Christine Clavel; Philippe Birembaut
Journal:  Crit Rev Oncol Hematol       Date:  2004-03       Impact factor: 6.312

3.  BAG3 controls angiogenesis through regulation of ERK phosphorylation.

Authors:  A Falco; M Festa; A Basile; A Rosati; M Pascale; F Florenzano; S L Nori; V Nicolin; M Di Benedetto; M L Vecchione; C Arra; A Barbieri; V De Laurenzi; M C Turco
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

4.  IKK{gamma} protein is a target of BAG3 regulatory activity in human tumor growth.

Authors:  Massimo Ammirante; Alessandra Rosati; Claudio Arra; Anna Basile; Antonia Falco; Michela Festa; Maria Pascale; Morena d'Avenia; Liberato Marzullo; Maria Antonietta Belisario; Margot De Marco; Antonio Barbieri; Aldo Giudice; Gennaro Chiappetta; Emilia Vuttariello; Mario Monaco; Patrizia Bonelli; Gaetano Salvatore; Maria Di Benedetto; Satish L Deshmane; Kamel Khalili; Maria Caterina Turco; Arturo Leone
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

5.  Caught in the middle: the role of Bag3 in disease.

Authors:  Andrea K McCollum; Giovanna Casagrande; Elise C Kohn
Journal:  Biochem J       Date:  2009-12-14       Impact factor: 3.857

6.  BAG3 protein regulates caspase-3 activation in HIV-1-infected human primary microglial cells.

Authors:  Alessandra Rosati; Kamel Khalili; Satish L Deshmane; Sujatha Radhakrishnan; Maria Pascale; M Caterina Turco; Liberato Marzullo
Journal:  J Cell Physiol       Date:  2009-02       Impact factor: 6.384

7.  An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators.

Authors:  S Takayama; Z Xie; J C Reed
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

8.  Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma.

Authors:  Iska Moxon-Emre; Eric Bouffet; Michael D Taylor; Normand Laperriere; Nadia Scantlebury; Nicole Law; Brenda J Spiegler; David Malkin; Laura Janzen; Donald Mabbott
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

9.  BAG3 regulates motility and adhesion of epithelial cancer cells.

Authors:  Masahiro Iwasaki; Sachiko Homma; Akinori Hishiya; Samuel J Dolezal; John C Reed; Shinichi Takayama
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

10.  Overexpressed BAG3 is a potential therapeutic target in chronic lymphocytic leukemia.

Authors:  Huayuan Zhu; Wei Wu; Yuan Fu; Wenyi Shen; Kourong Miao; Min Hong; Wei Xu; Ken H Young; Peng Liu; Jianyong Li
Journal:  Ann Hematol       Date:  2013-08-25       Impact factor: 3.673

View more
  3 in total

Review 1.  At the Crossroads of Apoptosis and Autophagy: Multiple Roles of the Co-Chaperone BAG3 in Stress and Therapy Resistance of Cancer.

Authors:  Donat Kögel; Benedikt Linder; Andreas Brunschweiger; Silvia Chines; Christian Behl
Journal:  Cells       Date:  2020-02-28       Impact factor: 6.600

2.  Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma.

Authors:  Jiang Deng; Qian Zhang; Liping Lv; Ping Ma; Yangyang Zhang; Ning Zhao; Yanyu Zhang
Journal:  Sci Rep       Date:  2022-04-29       Impact factor: 4.996

3.  BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.

Authors:  Sarah Shields; Emer Conroy; Tony O'Grady; Alo McGoldrick; Kate Connor; Mark P Ward; Zivile Useckaite; Eugene Dempsey; Rebecca Reilly; Yue Fan; Anthony Chubb; David Gomez Matallanas; Elaine W Kay; Darran O'Connor; Amanda McCann; William M Gallagher; Judith A Coppinger
Journal:  Oncotarget       Date:  2018-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.